

Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

NCT07369063

Status	RECRUITING
Phase	Phase 2
Sponsor	Northwell Health
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (8)

- All new pediatric participants aged 9-17 years with a new diagnosis of GD who will be started on methimazole, will be offered to participate at the time of diagnosis.
- Biochemical features include:
 - Suppressed TSH ≤ 0.1 .
 - Elevated T3
 - Elevated Free T4
- ... and 3 more (see full listing online)

Exclusion (10)

- Initial hydroxy vitamin D levels > 80 ng/mL
- Hypocalcemia, corrected calcium based on albumin < 8.4 mg/dL
- Hypercalcemia, corrected calcium based on albumin > 10.5 mg/dL
- Conditions that affect vitamin D metabolism such as: malabsorption, chronic kidney or liver disease, nephrocalcinosis, hyperparathyroidism
- Current use of medications which are known to affect thyroid function or vitamin D metabolism such as thyroid hormone replacement, corticosteroids, anticonvulsants
- ... and 5 more (see full listing online)

Locations (1 total)

Pediatric Endocrinology at Northwell Health, New Hyde Park, New York, United States

<https://clinicaltrials.gov/study/NCT07369063>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).